Cargando…

Dosimetry methods and clinical applications in peptide receptor radionuclide therapy for neuroendocrine tumours: a literature review

BACKGROUND: The main challenge for systemic radiation therapy using radiopharmaceuticals (SRT) is to optimise the dose delivered to the tumour, while minimising normal tissue irradiation. Dosimetry could help to increase therapy response and decrease toxicity after SRT by individual treatment planni...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huizing, Daphne Merel Valerie, de Wit-van der Veen, Berlinda Jantina, Verheij, Marcel, Stokkel, Marcellus Petrus Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6115319/ https://www.ncbi.nlm.nih.gov/pubmed/30159614 http://dx.doi.org/10.1186/s13550-018-0443-z

Ejemplares similares

A head-to-head comparison between two commercial software packages for hybrid dosimetry after peptide receptor radionuclide therapy
por: Huizing, Daphne M. V., et al.
Publicado: (2020)

Early response assessment and prediction of overall survival after peptide receptor radionuclide therapy
por: Huizing, Daphne M. V., et al.
Publicado: (2020)

Haematotoxicity during peptide receptor radionuclide therapy: Baseline parameters differences and effect on patient’s therapy course
por: de Vries–Huizing, Daphne M. V., et al.
Publicado: (2021)

(177)Lutetium SPECT/CT: Evaluation of collimator, photopeak and scatter correction
por: Huizing, Daphne M. V., et al.
Publicado: (2020)

Multicentre quantitative (68)Ga PET/CT performance harmonisation
por: Huizing, Daphne M. V., et al.
Publicado: (2019)

Australian experience of peptide receptor radionuclide therapy in lung neuroendocrine tumours
por: Lim, Lisi Elizabeth, et al.
Publicado: (2020)

Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours
por: Elston, Marianne S., et al.
Publicado: (2021)

Successful neoadjuvant peptide receptor radionuclide therapy for an inoperable pancreatic neuroendocrine tumour
por: da Silva, Tiago Nunes, et al.
Publicado: (2018)

Theranostics: radionuclide imaging and therapy in neuroendocrine tumours
por: Drake, Brent, et al.
Publicado: (2015)

Day-to-day variability of [(68)Ga]Ga-PSMA-11 accumulation in primary prostate cancer: effects on tracer uptake and visual interpretation
por: olde Heuvel, Judith, et al.
Publicado: (2020)

Feasibility of simplifying renal dosimetry in (177)Lu peptide receptor radionuclide therapy
por: Sundlöv, Anna, et al.
Publicado: (2018)

The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
por: Zaknun, John J., et al.
Publicado: (2013)

Radiation precautions for inpatient and outpatient (177)Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours
por: Levart, D., et al.
Publicado: (2019)

The consequences of a new software package for the quantification of gated-SPECT myocardial perfusion studies
por: van der Veen, Berlinda J., et al.
Publicado: (2010)

Assessment of global cardiac I-123 MIBG uptake and washout using volumetric quantification of SPECT acquisitions
por: van der Veen, Berlinda J., et al.
Publicado: (2012)

Simplified dosimetry for kidneys and tumors in (177)Lu-labeled peptide receptor radionuclide therapy
por: Ardenfors, Oscar, et al.
Publicado: (2022)

Current use and future potential of (physiologically based) pharmacokinetic modelling of radiopharmaceuticals: a review
por: Siebinga, Hinke, et al.
Publicado: (2022)

Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs)
por: Sowa-Staszczak, Anna, et al.
Publicado: (2011)

Erratum to: The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
por: Bodei, L., et al.
Publicado: (2013)

Peptide Receptor Radionuclide Therapy (PRRT) with (177)Lu-DOTATATE; Differences in Tumor Dosimetry, Vascularity and Lesion Metrics in Pancreatic and Small Intestinal Neuroendocrine Neoplasms
por: Jahn, Ulrika, et al.
Publicado: (2021)

Salvage peptide receptor radionuclide therapy with [(177)Lu-DOTA,Tyr(3)]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours
por: van der Zwan, W. A., et al.
Publicado: (2018)

Renal and Red Marrow Dosimetry in Peptide Receptor Radionuclide Therapy: 20 Years of History and Ahead
por: Walrand, Stephan, et al.
Publicado: (2021)

Clinical radionuclide therapy dosimetry: the quest for the “Holy Gray”
por: Brans, B., et al.
Publicado: (2007)

Hybrid Imaging for Patient-Specific Dosimetry in Radionuclide Therapy
por: Ljungberg, Michael, et al.
Publicado: (2015)

Effect of Peptide Dose on Radiation Dosimetry for Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATOC: A Pilot Study
por: Prasad, Vikas, et al.
Publicado: (2021)

Software-assisted dosimetry in peptide receptor radionuclide therapy with (177)Lutetium-DOTATATE for various imaging scenarios
por: Kupitz, Dennis, et al.
Publicado: (2017)

Reducing the number of CTs performed to monitor personalized dosimetry during peptide receptor radionuclide therapy (PRRT)
por: Chicheportiche, Alexandre, et al.
Publicado: (2018)

Apparent pacemaker dysfunction during peptide receptor radionuclide therapy for neuroendocrine tumor
por: Asbach, Stefan, et al.
Publicado: (2017)

Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: Recent Insights
por: Starr, Jason S, et al.
Publicado: (2020)

Safety and Efficacy of Peptide-Receptor Radionuclide Therapy in Elderly Neuroendocrine Tumor Patients
por: Theiler, Deborah, et al.
Publicado: (2021)

Radiation protection dosimetry: radionuclides and radiation protection data handbook
por: Nucl. Techn. Publ.
Publicado: (2002)

Quantitative Imaging for Targeted Radionuclide Therapy Dosimetry - Technical Review
por: Li, Tiantian, et al.
Publicado: (2017)

Personalized Dosimetry for Radionuclide Therapy Using Molecular Imaging Tools
por: Ljungberg, Michael, et al.
Publicado: (2016)

Individualised (177)Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
por: Sundlöv, Anna, et al.
Publicado: (2017)

Added-value of molecular imaging in myocardial metastasis of an ileal neuroendocrine tumour treated with peptide receptor radionuclide therapy: a case report
por: Mallón Araujo, María Del Carmen, et al.
Publicado: (2021)

Bone marrow dosimetry in peptide receptor radionuclide therapy with [(177)Lu-DOTA(0),Tyr(3)]octreotate
por: Forrer, Flavio, et al.
Publicado: (2009)

EANM Dosimetry Committee series on standard operational procedures for internal dosimetry for (131)I mIBG treatment of neuroendocrine tumours
por: Gear, Jonathan, et al.
Publicado: (2020)

Retrospective study of peptide receptor radionuclide therapy for Japanese patients with advanced neuroendocrine tumors
por: Kobayashi, Noritoshi, et al.
Publicado: (2021)

Theranostic SPECT reconstruction for improved resolution: application to radionuclide therapy dosimetry
por: Marquis, H., et al.
Publicado: (2021)

An anthropomorphic body phantom for the determination of calibration factor in radionuclide treatment dosimetry
por: Kovan, Bilal, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_p334tph7ri7qp3q43klg0nv1i8